<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34609083</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2052-1707</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Pharmacology research &amp; perspectives</Title><ISOAbbreviation>Pharmacol Res Perspect</ISOAbbreviation></Journal><ArticleTitle>Immunomodulation induced by central nervous system-related peptides as a therapeutic strategy for neurodegenerative disorders.</ArticleTitle><Pagination><StartPage>e00795</StartPage><MedlinePgn>e00795</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00795</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/prp2.795</ELocationID><Abstract><AbstractText>Neurodegenerative diseases (NDD) are disorders characterized by the progressive loss of neurons affecting motor, sensory, and/or cognitive functions. The incidence of these diseases is increasing and has a great impact due to their high morbidity and mortality. Unfortunately, current therapeutic strategies only temporarily improve the patients' quality of life but are insufficient for completely alleviating the symptoms. An interaction between the immune system and the central nervous system (CNS) is widely associated with neuronal damage in NDD. Usually, immune cell infiltration has been identified with inflammation and is considered harmful to the injured CNS. However, the immune system has a crucial role in the protection and regeneration of the injured CNS. Nowadays, there is a consensus that deregulation of immune homeostasis may represent one of the key initial steps in NDD. Dr. Michal Schwartz originally conceived the concept of "protective autoimmunity" (PA) as a well-controlled peripheral inflammatory reaction after injury, essential for neuroprotection and regeneration. Several studies suggested that immunizing with a weaker version of the neural self-antigen would generate PA without degenerative autoimmunity. The development of CNS-related peptides with immunomodulatory neuroprotective effect led to important research to evaluate their use in chronic and acute NDD. In this review, we refer to the role of PA and the potential applications of active immunization as a therapeutic option for NDD treatment. In particular, we focus on the experimental and clinical promissory findings for CNS-related peptides with beneficial immunomodulatory effects.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Pharmacology Research &amp; Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palumbo</LastName><ForeName>Mar&#xed;a Laura</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires (CIT NOBA)-UNNOBA-UNsADA-CONICET, Jun&#xed;n, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moroni</LastName><ForeName>Alejandro David</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires (CIT NOBA)-UNNOBA-UNsADA-CONICET, Jun&#xed;n, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quiroga</LastName><ForeName>Sof&#xed;a</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Instituto de Investigaciones Biom&#xe9;dicas, Consejo Nacional de Investigaciones Cient&#xed;ficas y T&#xe9;cnicas (CONICET, Pontificia Universidad Cat&#xf3;lica Argentina, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro</LastName><ForeName>Mar&#xed;a Micaela</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires (CIT NOBA)-UNNOBA-UNsADA-CONICET, Jun&#xed;n, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgue&#xf1;o</LastName><ForeName>Adriana Laura</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Instituto de Investigaciones Biom&#xe9;dicas, Consejo Nacional de Investigaciones Cient&#xed;ficas y T&#xe9;cnicas (CONICET, Pontificia Universidad Cat&#xf3;lica Argentina, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genaro</LastName><ForeName>Ana Mar&#xed;a</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0003-0027-3503</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaciones Biom&#xe9;dicas, Consejo Nacional de Investigaciones Cient&#xed;ficas y T&#xe9;cnicas (CONICET, Pontificia Universidad Cat&#xf3;lica Argentina, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharmacol Res Perspect</MedlineTA><NlmUniqueID>101626369</NlmUniqueID><ISSNLinking>2052-1707</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004676">Myelin Basic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C115314">myelin basic protein 87-99</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C416504">poly(tyrosyl-glutamic acid)</NameOfSubstance></Chemical><Chemical><RegistryNumber>5M691HL4BO</RegistryNumber><NameOfSubstance UI="D000068717">Glatiramer Acetate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068717" MajorTopicYN="N">Glatiramer Acetate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056747" MajorTopicYN="N">Immunomodulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004676" MajorTopicYN="N">Myelin Basic Protein</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009416" MajorTopicYN="N">Nerve Regeneration</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066829" MajorTopicYN="N">Neuroprotection</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057165" MajorTopicYN="N">Proteostasis Deficiencies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013119" MajorTopicYN="N">Spinal Cord Injuries</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CNS-related peptides</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">protective autoimmunity</Keyword></KeywordList><CoiStatement>The authors have indicated that they have no conflicts of interest regarding the content of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>5</Day><Hour>8</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34609083</ArticleId><ArticleId IdType="pmc">PMC8491457</ArticleId><ArticleId IdType="doi">10.1002/prp2.795</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ragagnin AMG, Shadfar S, Vidal M, Jamali MS, Atkin JD. Motor neuron susceptibility in ALS/FTD. Frontiers Neuroscience. 2019;13:532. 10.3389/fnins.2019.00532</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00532</ArticleId><ArticleId IdType="pmc">PMC6610326</ArticleId><ArticleId IdType="pubmed">31316328</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Bennett DA, Blennow K, et al.; Contributors . NIA&#x2010;AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535&#x2010;562. 10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalia LV, Lang AE. Parkinson&#x2019;s disease. Lancet. 2015;386(9996):896&#x2010;912. 10.1016/S0140-6736(14)61393-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)61393-3</ArticleId><ArticleId IdType="pubmed">25904081</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer's disease facts and figures. Alzheimers Dement. 2021;17(3):327&#x2010;406. 10.1002/alz.12328</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12328</ArticleId><ArticleId IdType="pubmed">33756057</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Hauben E, Schwartz M. Morphological aspects of spinal cord autoimmune neuroprotection: colocalization of T cells with B7&#x2013;2 (CD86) and prevention of cyst formation. FASEB J. 2001;15(6):1065&#x2010;1067. 10.1096/fj.00-0550fje</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.00-0550fje</ArticleId><ArticleId IdType="pubmed">11292669</ArticleId></ArticleIdList></Reference><Reference><Citation>Popovich PG, Stokes BT, Whitacre CC. Concept of autoimmunity following spinal cord injury: possible roles for T lymphocytes in the traumatized central nervous system. J Neurosci Res. 1996;45(4):349&#x2010;363. 10.1002/(SICI)1097-4547(19960815)45:4&lt;349:AID-JNR4&gt;3.0.CO;2-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19960815)45:4&lt;349:AID-JNR4&gt;3.0.CO;2-9</ArticleId><ArticleId IdType="pubmed">8872895</ArticleId></ArticleIdList></Reference><Reference><Citation>James SL, Theadom A, Ellenbogen RG, Bannick MS; GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators . Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990&#x2010;2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):56&#x2013;87. 10.1016/S1474-4422(18)30415-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30415-0</ArticleId><ArticleId IdType="pmc">PMC6291456</ArticleId><ArticleId IdType="pubmed">30497965</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics&#x2010;2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56&#x2010;e528. 10.1161/CIR.0000000000000659</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000659</ArticleId><ArticleId IdType="pubmed">30700139</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M. Physiological approaches to neuroprotection. boosting of protective autoimmunity. Surv Ophthalmol. 2001;45(Suppl 3):S256&#x2010;S260. 10.1016/S0039-6257(01)00208-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0039-6257(01)00208-9</ArticleId><ArticleId IdType="pubmed">11377445</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauben E, Butovsky O, Nevo U, et al. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J Neurosci. 2000;20(17):6421&#x2010;6430. 10.1523/JNEUROSCI.20-17-06421.2000</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-17-06421.2000</ArticleId><ArticleId IdType="pmc">PMC6772980</ArticleId><ArticleId IdType="pubmed">10964948</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauben E, Nevo U, Yoles E, et al. Autoimmune T cells as potential neuroprotective therapy for spinal cord injury. Lancet. 2000;355(9200):286&#x2010;287. 10.1016/s0140-6736(99)05140-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(99)05140-5</ArticleId><ArticleId IdType="pubmed">10675079</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol Rev. 2006;213:48&#x2010;65. 10.1111/j.1600-065X.2006.00441.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2006.00441.x</ArticleId><ArticleId IdType="pmc">PMC2633103</ArticleId><ArticleId IdType="pubmed">16972896</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziv Y, Ron N, Butovsky O, et al. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat Neurosci. 2006;9(2):268&#x2010;275. 10.1038/nn1629</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1629</ArticleId><ArticleId IdType="pubmed">16415867</ArticleId></ArticleIdList></Reference><Reference><Citation>Costantini E, D'Angelo C, Reale M. The role of immunosenescence in neurodegenerative diseases. Mediators Inflamm. 2018;2018:6039171. 10.1155/2018/6039171</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/6039171</ArticleId><ArticleId IdType="pmc">PMC5863336</ArticleId><ArticleId IdType="pubmed">29706800</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachiller S, Jim&#xe9;nez&#x2010;Ferrer I, Paulus A, et al. Microglia in neurological diseases: a road map to brain&#x2010;disease dependent&#x2010;inflammatory response. Front Cell Neurosci. 2018;12:488. 10.3389/fncel.2018.00488</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00488</ArticleId><ArticleId IdType="pmc">PMC6305407</ArticleId><ArticleId IdType="pubmed">30618635</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukahara T, Haniu H, Uemura T, Matsuda Y. Therapeutic potential of porcine liver decomposition product: new insights and perspectives for microglia&#x2010;mediated neuroinflammation in neurodegenerative diseases. Biomedicines. 2020;8(11):446.10.3390/biomedicines8110446</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines8110446</ArticleId><ArticleId IdType="pmc">PMC7690401</ArticleId><ArticleId IdType="pubmed">33105637</ArticleId></ArticleIdList></Reference><Reference><Citation>Moalem G, Leibowitz&#x2010;Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med. 1999;5(1):49&#x2010;55. 10.1038/4734</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/4734</ArticleId><ArticleId IdType="pubmed">9883839</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M, Moalem G, Leibowitz&#x2010;Amit R, Cohen IR. Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci. 1999;22(7):295&#x2010;299. 10.1016/s0166-2236(99)01405-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0166-2236(99)01405-8</ArticleId><ArticleId IdType="pubmed">10370250</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M, Kipnis J. Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries. Trends Mol Med. 2001;7(6):252&#x2010;258. 10.1016/s1471-4914(01)01993-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1471-4914(01)01993-1</ArticleId><ArticleId IdType="pubmed">11378514</ArticleId></ArticleIdList></Reference><Reference><Citation>Shechter R, Miller O, Yovel G, et al. Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity. 2013;38(3):555&#x2010;569. 10.1016/j.immuni.2013.02.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.02.012</ArticleId><ArticleId IdType="pmc">PMC4115271</ArticleId><ArticleId IdType="pubmed">23477737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunis G, Baruch K, Miller O, Schwartz M. Immunization with a Myelin&#x2010;derived antigen activates the brain's choroid plexus for recruitment of immunoregulatory cells to the CNS and attenuates disease progression in a mouse model of ALS. J Neurosci. 2015;35(16):6381&#x2010;6393. 10.1523/JNEUROSCI.3644-14.2015</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3644-14.2015</ArticleId><ArticleId IdType="pmc">PMC6605216</ArticleId><ArticleId IdType="pubmed">25904790</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775&#x2010;787. 10.1016/j.cell.2008.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2008.05.009</ArticleId><ArticleId IdType="pubmed">18510923</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol. 2007;8(2):191&#x2010;197. 10.1038/ni1428</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1428</ArticleId><ArticleId IdType="pubmed">17136045</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol. 2007;82(5):1083&#x2010;1094. 10.1189/jlb.0507296</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0507296</ArticleId><ArticleId IdType="pubmed">17675560</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh JT, Kipnis J. Regulatory T cells in CNS injury: the simple, the complex and the confused. Trends Mol Med. 2011;17(10):541&#x2010;547. 10.1016/j.molmed.2011.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2011.05.012</ArticleId><ArticleId IdType="pmc">PMC3189297</ArticleId><ArticleId IdType="pubmed">21741881</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh JT, Zheng J, Smirnov I, Lorenz U, Tung K, Kipnis J. Regulatory T cells in central nervous system injury: a double&#x2010;edged sword. J Immunol. 2014;193(10):5013&#x2010;5022. 10.4049/jimmunol.1302401</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1302401</ArticleId><ArticleId IdType="pmc">PMC4225170</ArticleId><ArticleId IdType="pubmed">25320276</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K, Rosenzweig N, Kertser A, et al. Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer's disease pathology. Nat Commun. 2015;6:7967. 10.1038/ncomms8967</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8967</ArticleId><ArticleId IdType="pmc">PMC4557123</ArticleId><ArticleId IdType="pubmed">26284939</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaked I, Tchoresh D, Gersner R, et al. Protective autoimmunity: interferon&#x2010;gamma enables microglia to remove glutamate without evoking inflammatory mediators. J Neurochem. 2005;92(5):997&#x2010;1009. 10.1111/j.1471-4159.2004.02954.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02954.x</ArticleId><ArticleId IdType="pubmed">15715651</ArticleId></ArticleIdList></Reference><Reference><Citation>Palumbo ML, Di Rosso ME, Simon EH, Gonzalez Murano MR, Genaro AM. Altered interferon&#x2010;&#x3b3; expression in lymphocytes as a potential peripheral marker of chronic stress&#x2010;induced cognitive deficit. Cytokine. 2018;107:26&#x2010;34. 10.1016/j.cyto.2017.11.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2017.11.010</ArticleId><ArticleId IdType="pubmed">29175260</ArticleId></ArticleIdList></Reference><Reference><Citation>Palumbo ML, Canzobre MC, Pascuan CG, R&#xed;os H, Wald M, Genaro AM. Stress induced cognitive deficit is differentially modulated in BALB/c and C57Bl/6 mice: correlation with Th1/Th2 balance after stress exposure. J Neuroimmunol. 2010;218(1&#x2013;2):12&#x2010;20. 10.1016/j.jneuroim.2009.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2009.11.005</ArticleId><ArticleId IdType="pubmed">19942299</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenkranz D, Weyer S, Tolosa E, et al. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol. 2007;188(1&#x2013;2):117&#x2010;127. 10.1016/j.jneuroim.2007.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2007.05.011</ArticleId><ArticleId IdType="pubmed">17582512</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres KC, Ara&#xfa;jo Pereira P, Lima GS, et al. Increased frequency of T cells expressing IL&#x2010;10 in Alzheimer disease but not in late&#x2010;onset depression patients. Prog Neuropsychopharmacol Biol Psychiatry. 2013;47:40&#x2010;45. 10.1016/j.pnpbp.2013.07.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2013.07.021</ArticleId><ArticleId IdType="pubmed">23954740</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosley RL, Gordon PH, Hasiak CM, Van Wetering FJ, Mitsumoto H, Gendelman HE. Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients. Amyotroph Lateral Scler. 2007;8(4):235&#x2010;242. 10.1080/17482960701374601</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701374601</ArticleId><ArticleId IdType="pubmed">17653922</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V, Drory VE, Leigh PN, Ludolph A, Robberecht W, Silani V. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double&#x2010; blind, randomized, multicentre, placebo&#x2010;controlled trial. Amyotroph Lateral Scler. 2009;10(5&#x2013;6):378&#x2010;383. 10.3109/17482960902803432</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902803432</ArticleId><ArticleId IdType="pubmed">19922128</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenkel D, Maron R, Burt DS, Weiner HL. Nasal vaccination with a proteosome&#x2010;based adjuvant and glatiramer acetate clears beta&#x2010;amyloid in a mouse model of Alzheimer disease. J Clin Invest. 2005;115(9):2423&#x2010;2433. 10.1172/JCI23241</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI23241</ArticleId><ArticleId IdType="pmc">PMC1184038</ArticleId><ArticleId IdType="pubmed">16100572</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Koronyo&#x2010;Hamaoui M, Kunis G, et al. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic&#x2010;like microglia expressing insulin&#x2010;like growth factor 1. Proc Natl Acad Sci USA. 2006;103(31):11784&#x2010;11789. 10.1073/pnas.0604681103</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0604681103</ArticleId><ArticleId IdType="pmc">PMC1544247</ArticleId><ArticleId IdType="pubmed">16864778</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Kunis G, Koronyo&#x2010;Hamaoui M, Schwartz M. Selective ablation of bone marrow&#x2010;derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model. Eur J Neurosci. 2007;26(2):413&#x2010;416. 10.1111/j.1460-9568.2007.05652.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2007.05652.x</ArticleId><ArticleId IdType="pubmed">17623022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakalash S, Pham M, Koronyo Y, et al. Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease. Invest Ophthalmol Vis Sci. 2011;52(12):9033&#x2010;9046. 10.1167/iovs.11-7498</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.11-7498</ArticleId><ArticleId IdType="pubmed">21969301</ArticleId></ArticleIdList></Reference><Reference><Citation>Koronyo Y, Salumbides BC, Sheyn J, et al. Therapeutic effects of glatiramer acetate and grafted CD115+ monocytes in a mouse model of Alzheimer's disease. Brain. 2015;138(Pt 8):2399&#x2010;2422. 10.1093/brain/awv150</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv150</ArticleId><ArticleId IdType="pmc">PMC4840949</ArticleId><ArticleId IdType="pubmed">26049087</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Hayden EY, Garcia VJ, et al. Activated bone marrow&#x2010;derived macrophages eradicate Alzheimer's&#x2010;related A&#x3b2;42 oligomers and protect synapses. Front Immunol. 2020;11:49. 10.3389/fimmu.2020.00049</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00049</ArticleId><ArticleId IdType="pmc">PMC7005081</ArticleId><ArticleId IdType="pubmed">32082319</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentsendorj A, Sheyn J, Fuchs D&#x2010;T, et al. A novel role for osteopontin in macrophage&#x2010;mediated amyloid&#x2010;&#x3b2; clearance in Alzheimer's models. Brain Behav Immun. 2018;67:163&#x2010;180. 10.1016/j.bbi.2017.08.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2017.08.019</ArticleId><ArticleId IdType="pmc">PMC5865478</ArticleId><ArticleId IdType="pubmed">28860067</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9):1553&#x2010;1562. 10.1212/01.WNL.0000159740.16984.3C</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000159740.16984.3C</ArticleId><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CY, Wang P&#x2010;N, Chiu M&#x2010;J, et al. UB&#x2010;311, a novel UBITh&#xae; amyloid &#x3b2; peptide vaccine for mild Alzheimer's disease. Alzheimers Dement. 2017;3(2):262&#x2010;272. 10.1016/j.trci.2017.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2017.03.005</ArticleId><ArticleId IdType="pmc">PMC5651432</ArticleId><ArticleId IdType="pubmed">29067332</ArticleId></ArticleIdList></Reference><Reference><Citation>Benner EJ, Mosley RL, Destache CJ, et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA. 2004;101(25):9435&#x2010;9440. 10.1073/pnas.0400569101</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0400569101</ArticleId><ArticleId IdType="pmc">PMC438994</ArticleId><ArticleId IdType="pubmed">15197276</ArticleId></ArticleIdList></Reference><Reference><Citation>Churchill MJ, Cantu MA, Kasanga EA, Moore C, Salvatore MF, Meshul CK. Glatiramer acetate reverses motor dysfunction and the decrease in tyrosine hydroxylase levels in a mouse model of Parkinson's disease. Neuroscience. 2019;414:8&#x2010;27. 10.1016/j.neuroscience.2019.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2019.06.006</ArticleId><ArticleId IdType="pubmed">31220543</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibarra A, Avenda&#xf1;o H, Cruz Y. Copolymer&#x2010;1 (Cop&#x2010;1) improves neurological recovery after middle cerebral artery occlusion in rats. Neurosci Lett. 2007;425(2):110&#x2010;113. 10.1016/j.neulet.2007.08.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2007.08.038</ArticleId><ArticleId IdType="pubmed">17868996</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz Y, Garc&#xed;a EE, G&#xe1;lvez JV, et al. Release of interleukin&#x2010;10 and neurotrophic factors in the choroid plexus: possible inductors of neurogenesis following copolymer&#x2010;1 immunization after cerebral ischemia. Neural Regen Res. 2018;13(10):1743&#x2010;1752. 10.4103/1673-5374.238615</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.238615</ArticleId><ArticleId IdType="pmc">PMC6128049</ArticleId><ArticleId IdType="pubmed">30136689</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft P, G&#xf6;bel K, Meuth SG, Kleinschnitz C. Glatiramer acetate does not protect from acute ischemic stroke in mice. Exp Transl Stroke Med. 2014;6(1):4. 10.1186/2040-7378-6-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2040-7378-6-4</ArticleId><ArticleId IdType="pmc">PMC3943273</ArticleId><ArticleId IdType="pubmed">24576335</ArticleId></ArticleIdList></Reference><Reference><Citation>Poittevin M, Deroide N, Azibani F, et al. Glatiramer Acetate administration does not reduce damage after cerebral ischemia in mice. J Neuroimmunol. 2013;254(1&#x2013;2):55&#x2010;62. 10.1016/j.jneuroim.2012.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2012.09.009</ArticleId><ArticleId IdType="pubmed">23026222</ArticleId></ArticleIdList></Reference><Reference><Citation>Askarifirouzjaei H, Khajoueinejad L, Salek Farrokhi A, et al. Implications of immunotherapy with high&#x2010;dose glatiramer acetate in acute phase of spinal cord injury in rats. Immunopharmacol Immunotoxicol. 2019;41(1):150&#x2010;162. 10.1080/08923973.2019.1566362</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08923973.2019.1566362</ArticleId><ArticleId IdType="pubmed">31038378</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a E, Silva&#x2010;Garc&#xed;a R, Mestre H, et al. Immunization with A91 peptide or copolymer&#x2010;1 reduces the production of nitric oxide and inducible nitric oxide synthase gene expression after spinal cord injury. J Neurosci Res. 2012;90(3):656&#x2010;663. 10.1002/jnr.22771</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22771</ArticleId><ArticleId IdType="pubmed">22002544</ArticleId></ArticleIdList></Reference><Reference><Citation>Kipnis J, Nevo U, Panikashvili D, et al. Therapeutic vaccination for closed head injury. J Neurotrauma. 2003;20(6):559&#x2010;569. 10.1089/089771503767168483</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/089771503767168483</ArticleId><ArticleId IdType="pubmed">12906740</ArticleId></ArticleIdList></Reference><Reference><Citation>Marciani DJ. A retrospective analysis of the Alzheimer's disease vaccine progress &#x2010; the critical need for new development strategies. J Neurochem. 2016;137(5):687&#x2010;700. 10.1111/jnc.13608</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13608</ArticleId><ArticleId IdType="pubmed">26990863</ArticleId></ArticleIdList></Reference><Reference><Citation>Agadjanyan MG, Petrovsky N, Ghochikyan A. A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease. Alzheimers Dement. 2015;11(10):1246&#x2010;1259. 10.1016/j.jalz.2015.06.1884</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.06.1884</ArticleId><ArticleId IdType="pmc">PMC4630107</ArticleId><ArticleId IdType="pubmed">26192465</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow MR, Andreasen N, Riviere M&#x2010;E, et al. Long&#x2010;term treatment with active A&#x3b2; immunotherapy with CAD106 in mild Alzheimer's disease. Alzheimers Res Ther. 2015;7(1):23. 10.1186/s13195-015-0108-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-015-0108-3</ArticleId><ArticleId IdType="pmc">PMC4410460</ArticleId><ArticleId IdType="pubmed">25918556</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenberghe R, Riviere M&#x2010;E, Caputo A, et al. Active A&#x3b2; immunotherapy CAD106 in Alzheimer's disease: a phase 2b study. Alzheimers Dement. 2017;3(1):10&#x2010;22. 10.1016/j.trci.2016.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2016.12.003</ArticleId><ArticleId IdType="pmc">PMC5651373</ArticleId><ArticleId IdType="pubmed">29067316</ArticleId></ArticleIdList></Reference><Reference><Citation>von Euler CM, Vorup&#x2010;Jensen T. Targets and mechanisms in prevention of Parkinson's disease through immunomodulatory treatments. Scand J Immunol. 2017;85(5):321&#x2010;330. 10.1111/sji.12542</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12542</ArticleId><ArticleId IdType="pubmed">28231624</ArticleId></ArticleIdList></Reference><Reference><Citation>Boost Vaccination Data Encourage Continued Development of AFFiRiS Therapeutic Parkinson's Disease Vaccine against Alpha Synuclein. Vienna, Austria: AFiRiS; 2016.</Citation></Reference><Reference><Citation>Blokhuis AM, Groen EJN, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125(6):777&#x2010;794. 10.1007/s00401-013-1125-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1125-6</ArticleId><ArticleId IdType="pmc">PMC3661910</ArticleId><ArticleId IdType="pubmed">23673820</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy EF. A prion&#x2010;like mechanism for the propagated misfolding of SOD1 from in silico modeling of solvated near&#x2010;native conformers. PLoS One. 2017;12(5):e0177284. 10.1371/journal.pone.0177284</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0177284</ArticleId><ArticleId IdType="pmc">PMC5417709</ArticleId><ArticleId IdType="pubmed">28472188</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibilla C, Bertolotti A. Prion properties of SOD1 in amyotrophic lateral sclerosis and potential therapy. Cold Spring Harb Perspect Biol. 2017;9(10): 10.1101/cshperspect.a024141</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024141</ArticleId><ArticleId IdType="pmc">PMC5630002</ArticleId><ArticleId IdType="pubmed">28096265</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao B, Marciniuk K, Gibbs E, Yousefi M, Napper S, Cashman NR. Therapeutic vaccines for amyotrophic lateral sclerosis directed against disease specific epitopes of superoxide dismutase 1. Vaccine. 2019;37(35):4920&#x2010;4927. 10.1016/j.vaccine.2019.07.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.07.044</ArticleId><ArticleId IdType="pubmed">31324499</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik R, Wiedau M. Therapeutic approaches targeting protein aggregation in amyotrophic lateral sclerosis. Front Mol Neurosci. 2020;13:98. 10.3389/fnmol.2020.00098</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.00098</ArticleId><ArticleId IdType="pmc">PMC7296057</ArticleId><ArticleId IdType="pubmed">32581709</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, O'Neill SM, Pozdnyakov N, et al. Passive immunotherapy targeting amyloid&#x2010;&#x3b2; reduces cerebral amyloid angiopathy and improves vascular reactivity. Brain. 2016;139(Pt 2):563&#x2010;577. 10.1093/brain/awv313</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv313</ArticleId><ArticleId IdType="pubmed">26493635</ArticleId></ArticleIdList></Reference><Reference><Citation>Montoliu&#x2010;Gaya L, Villegas S. A&#x3b2;&#x2010;Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment. Expert Rev Mol Med. 2016;18:e13. 10.1017/erm.2016.11</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/erm.2016.11</ArticleId><ArticleId IdType="pubmed">27357999</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing&#x2010;remitting multiple sclerosis: results of a phase III multicenter, double&#x2010;blind placebo&#x2010;controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268&#x2010;1276. 10.1212/wnl.45.7.1268</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.45.7.1268</ArticleId><ArticleId IdType="pubmed">7617181</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziemssen T, Ashtamker N, Rubinchick S, Knappertz V, Comi G. Long&#x2010;term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis. Expert Opin Drug Saf. 2017;16(2):247&#x2010;255. 10.1080/14740338.2017.1274728</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2017.1274728</ArticleId><ArticleId IdType="pubmed">27989217</ArticleId></ArticleIdList></Reference><Reference><Citation>De Kleijn KMA, Martens GJM. Molecular effects of FDA&#x2010;approved multiple sclerosis drugs on glial cells and neurons of the central nervous system. Int J Mol Sci. 2020;21(12):4229. 10.3390/ijms21124229</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21124229</ArticleId><ArticleId IdType="pmc">PMC7352301</ArticleId><ArticleId IdType="pubmed">32545828</ArticleId></ArticleIdList></Reference><Reference><Citation>Liblau R. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti&#x2010;inflammatory and neuroprotective role. J Neurol Sci. 2009;287:S17&#x2010;S23. 10.1016/S0022-510X(09)71296-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(09)71296-1</ArticleId><ArticleId IdType="pubmed">20106343</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnon R, Aharoni R. Neurogenesis and neuroprotection in the CNS&#x2013;fundamental elements in the effect of Glatiramer acetate on treatment of autoimmune neurological disorders. Mol Neurobiol. 2007;36:245&#x2010;253. 10.1007/s12035-007-8002-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-007-8002-z</ArticleId><ArticleId IdType="pubmed">17955199</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhib&#x2010;Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology. 2002;58(8 Suppl 4):S3&#x2010;S9. 10.1212/wnl.58.8_suppl_4.s3</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.58.8_suppl_4.s3</ArticleId><ArticleId IdType="pubmed">11971121</ArticleId></ArticleIdList></Reference><Reference><Citation>Palumbo ML, Trinchero MF, Zorrilla&#x2010;Zubilete MA, Schinder AF, Genaro AM. Glatiramer acetate reverts stress&#x2010;induced alterations on adult neurogenesis and behavior. Involvement of Th1/Th2 balance. Brain Behav Immun. 2012;26(3):429&#x2010;438. 10.1016/j.bbi.2011.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2011.12.006</ArticleId><ArticleId IdType="pubmed">22200600</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewitus GM, Wilf&#x2010;Yarkoni A, Ziv Y, et al. Vaccination as a novel approach for treating depressive behavior. Biol Psychiatry. 2009;65(4):283&#x2010;288. 10.1016/j.biopsych.2008.07.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2008.07.014</ArticleId><ArticleId IdType="pubmed">18722594</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Doorish C, Montes J, et al. Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology. 2006;66(7):1117&#x2010;1119. 10.1212/01.wnl.0000204235.81272.e2</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000204235.81272.e2</ArticleId><ArticleId IdType="pubmed">16606934</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;land L&#x2010;C, Markovinovic A, Jakovac H, et al. Immunity in amyotrophic lateral sclerosis: blurred lines between excessive inflammation and inefficient immune responses. Brain Commun. 2020;2(2):fcaa124. 10.1093/braincomms/fcaa124</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa124</ArticleId><ArticleId IdType="pmc">PMC7585698</ArticleId><ArticleId IdType="pubmed">33134918</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. are we any closer to registering a new treatment? Front Aging Neurosci. 2017;9(68):1&#x2010;11. 10.3389/fnagi.2017.00068</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Scorisa JM, Zanon RG, Freria CM, de Oliveira ALR. Glatiramer acetate positively influences spinal motoneuron survival and synaptic plasticity after ventral root avulsion. Neurosci Lett. 2009;451(1):34&#x2010;39. 10.1016/j.neulet.2008.12.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2008.12.017</ArticleId><ArticleId IdType="pubmed">19103252</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz Y, Lorea J, Mestre H, et al. Copolymer&#x2010;1 promotes neurogenesis and improves functional recovery after acute ischemic stroke in rats. PLoS One. 2015;10(3):e0121854. 10.1371/journal.pone.0121854</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0121854</ArticleId><ArticleId IdType="pmc">PMC4378896</ArticleId><ArticleId IdType="pubmed">25821957</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibarra A, Garc&#xed;a E, Flores N, et al. Immunization with neural&#x2010;derived antigens inhibits lipid peroxidation after spinal cord injury. Neurosci Lett. 2010;476(2):62&#x2010;65. 10.1016/j.neulet.2010.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2010.04.003</ArticleId><ArticleId IdType="pubmed">20381587</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez&#x2010;Barrera R, Fern&#xe1;ndez&#x2010;Presas AM, Garc&#xed;a E, et al. Immunization with a neural&#x2010;derived peptide protects the spinal cord from apoptosis after traumatic injury. Biomed Res Int. 2013;2013:827517. 10.1155/2013/827517</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/827517</ArticleId><ArticleId IdType="pmc">PMC3819886</ArticleId><ArticleId IdType="pubmed">24236295</ArticleId></ArticleIdList></Reference><Reference><Citation>Marti&#xf1;&#xf3;n S, Garc&#xed;a&#x2010;Vences E, Toscano&#x2010;Tejeida D, et al. Long&#x2010;term production of BDNF and NT&#x2010;3 induced by A91&#x2010;immunization after spinal cord injury. BMC Neurosci. 2016;17(1):42. 10.1186/s12868-016-0267-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12868-016-0267-6</ArticleId><ArticleId IdType="pmc">PMC4928355</ArticleId><ArticleId IdType="pubmed">27364353</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez&#x2010;Barrera R, Flores&#x2010;Romero A, Garc&#xed;a E, et al. Immunization with neural&#x2010;derived peptides increases neurogenesis in rats with chronic spinal cord injury. CNS Neurosci Ther. 2020;26(6):650&#x2010;658. 10.1111/cns.13368</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.13368</ArticleId><ArticleId IdType="pmc">PMC7248545</ArticleId><ArticleId IdType="pubmed">32352656</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a E, Silva&#x2010;Garc&#xed;a R, Flores&#x2010;Romero A, Blancas&#x2010;Espinoza L, Rodr&#xed;guez&#x2010;Barrera R, Ibarra A. The severity of spinal cord injury determines the inflammatory gene expression pattern after immunization with neural&#x2010;derived peptides. J Mol Neurosci. 2018;65(2):190&#x2010;195. 10.1007/s12031-018-1077-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-018-1077-3</ArticleId><ArticleId IdType="pubmed">29796836</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradbury EJ, Burnside ER. Moving beyond the glial scar for spinal cord repair. Nat Commun. 2019;10(1):3879. 10.1038/s41467-019-11707-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11707-7</ArticleId><ArticleId IdType="pmc">PMC6713740</ArticleId><ArticleId IdType="pubmed">31462640</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales I&#x2010;I, Toscano&#x2010;Tejeida D, Ibarra A. Non pharmacological strategies to promote spinal cord regeneration: a view on some individual or combined approaches. Curr Pharm Des. 2016;22(6):720&#x2010;727. 10.2174/1381612822666151204001103</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612822666151204001103</ArticleId><ArticleId IdType="pubmed">26635267</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez&#x2010;Barrera R, Flores&#x2010;Romero A, Fern&#xe1;ndez&#x2010;Presas AM, et al. Immunization with neural derived peptides plus scar removal induces a permissive microenvironment, and improves locomotor recovery after chronic spinal cord injury. BMC Neurosci. 2017;18(1):7. 10.1186/s12868-016-0331-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12868-016-0331-2</ArticleId><ArticleId IdType="pmc">PMC5217189</ArticleId><ArticleId IdType="pubmed">28056790</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez&#x2010;Barrera R, Flores&#x2010;Romero A, Buzoianu&#x2010;Anguiano V, et al. Use of a combination strategy to improve morphological and functional recovery in rats with chronic spinal cord injury. Front Neurol. 2020;11:189. 10.3389/fneur.2020.00189</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00189</ArticleId><ArticleId IdType="pmc">PMC7142263</ArticleId><ArticleId IdType="pubmed">32300328</ArticleId></ArticleIdList></Reference><Reference><Citation>Parra&#x2010;Villamar D, Blancas&#x2010;Espinoza L, Garcia&#x2010;Vences E, et al. Neuroprotective effect of immunomodulatory peptides in rats with traumatic spinal cord injury. Neural Regen Res. 2021;16(7):1273&#x2010;1280. 10.4103/1673-5374.301485</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.301485</ArticleId><ArticleId IdType="pmc">PMC8284257</ArticleId><ArticleId IdType="pubmed">33318405</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang K, Chao R, et al. Neuroprotective effect of vaccination with autoantigen&#x2010;pulsed dendritic cells after spinal cord injury. J Surg Res. 2012;176(1):281&#x2010;292. 10.1016/j.jss.2011.06.066</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2011.06.066</ArticleId><ArticleId IdType="pubmed">21872882</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Chao R, Guo QN, et al. Expressions of some neurotrophins and neurotrophic cytokines at site of spinal cord injury in mice after vaccination with dendritic cells pulsed with homogenate proteins. NeuroImmunoModulation. 2013;20(2):87&#x2010;98. 10.1159/000345522</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000345522</ArticleId><ArticleId IdType="pubmed">23257628</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Li J, Kong P, et al. Enhanced expression of neurotrophic factors in the injured spinal cord through vaccination with myelin basic protein&#x2010;derived peptide pulsed dendritic cells. Spine. 2015;40(2):95&#x2013;101. 10.1097/BRS.0000000000000694</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BRS.0000000000000694</ArticleId><ArticleId IdType="pubmed">25569526</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady CT, Lahn M, Vollmer M, et al. Response of murine gamma delta T cells to the synthetic polypeptide poly&#x2010;Glu50Tyr50. J Immunol. 2000;165(4):1790&#x2010;1798. 10.4049/jimmunol.165.4.1790</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.165.4.1790</ArticleId><ArticleId IdType="pubmed">10925256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziv Y, Finkelstein A, Geffen Y, et al. A novel immune&#x2010;based therapy for stroke induces neuroprotection and supports neurogenesis. Stroke. 2007;38(2 Suppl):774&#x2010;782. 10.1161/01.STR.0000255784.27298.23</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.0000255784.27298.23</ArticleId><ArticleId IdType="pubmed">17261737</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakalash S, Yoles E, Geffen Y. Glu&#x2010;Tyr polypeptide (Poly&#x2013;YE) vaccination for acute and chronic glaucoma. Invest Ophthalmol Vis Sci. 2004;45(13):910.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>